

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

17<sup>th</sup> June, 2025

The Manager,  
Listing Compliance Department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400051

Symbol: SAKAR

Dear Sir,

**Sub: Intimation of allotment of 3,00,000 Equity Shares upon conversion of Fully Convertible Warrants – through Circular Resolution passed on 17<sup>th</sup> June, 2025**

**Ref.: - NSE 'In principle' approval granted vide Ref. no. Ref: NSE/LIST/38623 dated 20<sup>th</sup> December, 2023 under Regulation 28(1) of SEBI (ICDR) Regulations, 2018**

This is in furtherance to the intimation given by the Company on 28<sup>th</sup> December, 2023 w.r.t. allotment of 5,00,000 Warrants (convertible into equal number of Equity Shares) of Rs. 10/- each (hereinafter referred as 'Convertible Warrants') at a price of Rs. 384/- per Convertible Warrant including premium of Rs. 374/- per Convertible Warrant to Promoters and Non-Promoters on Preferential basis. We also draw your attention to intimation dated 27<sup>th</sup> December, 2024 for allotment of 2,00,000 Equity Shares upon conversion of 2,00,000 Warrants.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Non-promoters as mentioned in Annexure - A have exercised their right for conversion of in aggregate 3,00,000 warrants into equal number of Equity Shares. Upon receipt of an amount of Rs. 288/- per share aggregating to Rs. 8,64,00,000/- (being 75% of the total consideration payable) ('Warrant Exercise Price'), the Board of Directors through Circular Resolution dated 17<sup>th</sup> June, 2025, has approved the allotment of total 3,00,000 Equity Shares of Rs. 10/- each, to the Non-Promoters as mentioned hereunder upon conversion of equal number of warrants.

Sr. No.	Name of Allottees (Warrant holders)	No. of warrants allotted on 28 <sup>th</sup> December, 2023 (a)	No. of warrants converted into equity shares till date (excluding present conversion) (b)	No. of warrants converted under present allotment (c)	No. of outstanding warrants to be converted into equity shares (a-b-c)
<b>Non-Promoters</b>					
1	Hi-Tech Chemicals Limited	2,00,000	Nil	2,00,000	Nil
2	Hemant Gadodia	34,000	Nil	34,000	Nil
3	Prakash Diwan	33,000	Nil	33,000	Nil
4	Sunil Kabra	33,000	Nil	33,000	Nil
	<b>Total</b>	<b>3,00,000</b>	<b>Nil</b>	<b>3,00,000</b>	<b>Nil</b>

The new Equity Shares so allotted, shall rank pari passu with the existing Equity Shares of the Company in all respects. Consequently, the Issued and Paid-up Capital of the Company stand increased to Rs. 22,24,99,100/- consisting of 2,22,49,910 Equity Shares of Rs.10/- each.



Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

After the said conversion, no outstanding warrants left for conversion.

The details as required under Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are given in Annexure – A to this letter.


We will approach you in due course of time for Listing Approval for the aforesaid allotment in terms of SEBI Listing Regulations.


We request you to kindly take the same on your records.

Thanking you,

Yours faithfully,

**FOR SAKAR HEALTHCARE LIMITED**

  
**BHARAT SONI**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**



The details as required under Regulation 30 of Listing Regulations read with SEBI Circular(s) are as under:

Sr. No.	Particulars of disclosure	Details																													
1.	Types of securities issued	Equity Shares pursuant to conversion of warrants																													
2.	Type of issuance/allotment	Preferential Issue - Allotment																													
3.	Total number of Securities issued	Allotment of 3,00,000 Equity Shares of face value Rs.10/- each upon conversion of equal number of warrants and upon receipt of balance 75% amount 'Warrant Exercise Price' aggregating to Rs. 8,64,00,000/-.																													
4.	a. Name of the investors	<p><b>Non-Promoters:</b></p> <ol style="list-style-type: none"> <li>Hemant Gadodia</li> <li>Prakash Diwan</li> <li>Sunil Kabra</li> <li>Hi-Tech Chemicals Limited</li> </ol>																													
	b. Post allotment of securities outcome of the subscription, issue price /allotted price (in case of convertibles), number of investors	<p><b>Outcome of allotment:</b></p> <table border="1"> <thead> <tr> <th rowspan="2">Investor/ Allottee</th> <th colspan="2">Pre-Issue equity shareholding</th> <th colspan="2">Post-issue/allotment Equity Shareholding</th> </tr> <tr> <th>No.</th> <th>%</th> <th>No.</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Hemant Gadodia</td> <td>NIL</td> <td>N.A.</td> <td>34,000</td> <td>0.15%</td> </tr> <tr> <td>Prakash Diwan</td> <td>20,000</td> <td>0.09</td> <td>33,000</td> <td>0.15%</td> </tr> <tr> <td>Sunil Kabra</td> <td>NIL</td> <td>N.A.</td> <td>33,000</td> <td>0.15%</td> </tr> <tr> <td>Hi-Tech Chemicals Limited</td> <td>NIL</td> <td>N.A.</td> <td>629699</td> <td>2.83%</td> </tr> </tbody> </table> <p><b>Issue Price:</b> Total 5,00,000 convertible warrants were issued to the proposed allottees on 28<sup>th</sup> December, 2023, carrying a right to subscribe to One Equity Share per warrant, upon receipt of an amount aggregating to Rs. 4,80,00,000/-, being 25% (of issue price of Rs.384/- per security) of the total consideration payable as upfront payment ('Warrant Subscription Price').</p> <p>Out of above 5,00,000 warrants, 2,00,000 warrants were converted into equal number of equity shares on 27<sup>th</sup> December, 2024.</p> <p>Now, 3,00,000 Equity Shares have been allotted on 17<sup>th</sup> June, 2025 to the Non-Promoters (allottees) upon receipt of balance amount aggregating to Rs. 8,64,00,000/- being 75% of total consideration payable ('Warrant Exercise Price').</p> <p><b>Number of Investors:</b> Allotment of 3,00,000 equity shares upon conversion of warrants is made to Four investors (Non-promoters) as mentioned above.</p>	Investor/ Allottee	Pre-Issue equity shareholding		Post-issue/allotment Equity Shareholding		No.	%	No.	%	Hemant Gadodia	NIL	N.A.	34,000	0.15%	Prakash Diwan	20,000	0.09	33,000	0.15%	Sunil Kabra	NIL	N.A.	33,000	0.15%	Hi-Tech Chemicals Limited	NIL	N.A.	629699	2.83%
Investor/ Allottee	Pre-Issue equity shareholding			Post-issue/allotment Equity Shareholding																											
	No.	%	No.	%																											
Hemant Gadodia	NIL	N.A.	34,000	0.15%																											
Prakash Diwan	20,000	0.09	33,000	0.15%																											
Sunil Kabra	NIL	N.A.	33,000	0.15%																											
Hi-Tech Chemicals Limited	NIL	N.A.	629699	2.83%																											



Sr. No.	Particulars of disclosure	
		Post present allotment, no outstanding warrants left for any conversion.
	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument	<p>The tenure of the 5,00,000 warrants shall not exceed 18 (eighteen) months from the date of allotment of warrants (i.e. 28<sup>th</sup> December, 2023). Each warrant carries a right to subscribe 1 (one) Equity Share per warrant, which may be exercised in one or more tranches during the period commencing from the date of allotment of warrants until the expiry of 18(eighteen) months from the date of allotment of the warrants.</p> <p>An amount equivalent to 25% of the Warrant Issue Price has been received at the time of subscription and allotment of each Warrant.</p> <p>As intimated to the exchange vide letter dated 27<sup>th</sup> December, 2024, 200,000 equity shares were allotted on 27<sup>th</sup> December, 2024 to allottees upon conversion and receipt of balance 75% Warrant Exercise Price.</p> <p>Now, on 17<sup>th</sup> June, 2025, 3,00,000 Equity Shares have been allotted to the Non-Promoters (allottees) upon receipt of balance 75% Warrant Exercise Price.</p> <p>All the warrants have been converted into equity and there are no outstanding warrants as on date.</p>
5.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable
6.	Lock in	The Equity Shares allotted upon conversion shall be subject to 'lock-in' as prescribed under the applicable provisions of Regulation 167 of SEBI (ICDR).

For SAKAR HEALTHCARE LIMITED

  
**BHARAT SONI**  
**COMPANY SECRETARY &**  
**COMPLIANCE OFFICER**

